Explore the Agenda

8:00 am Morning Coffee and Check-in

8:55 am Chair’s Opening Remarks

Medical Transformation & New Product Planning Lead, Specialty Care NA Medical & MedDev Lead, Sanofi

Redefining the Evolving Role of Medical Affairs to Drive Practice Change & Patient Impact

9:00 am The Future of Medical Affairs, Evolving from a Support Function to a Strategic Driver of Business & Patient Impact

Head of Global Medical Affairs, Merz Pharmaceuticals LLC
  • Explore how Medical Affairs is transforming into a core, data-led pillar that shapes clinical, commercial, and patient outcomes in an increasingly complex healthcare landscape.
  • Learn practical strategies to increase visibility, translate scientific insights into business-relevant outcomes, and position Medical Affairs as an indispensable strategic partner.
  • Uncover how patient-centric value communication, and behavior-change measurement are redefining success in modern Medical Affairs.

9:30 am Precision Medical Engagement: Navigating the Scientific Journey Through E2E Impact Analytics

Senior Medical Experience Director, Genentech
  • Establish clear objectives for every engagement—moving beyond scientific exchange to specifically target knowledge gaps, clinical confidence, and therapeutic adoption.
  • Identify which Medical Affairs activities are most effective in driving measurable behavioural change among healthcare professionals
  • Learn how to embed an end-to-end measurement framework across Field Medical and internal teams

10:00 am Morning Break & Speed Networking

The ideal opportunity to get face-to-face with many global Medical Affairs leaders for important in-depth conversations.

11:00 am Defining True Value for Senior Leadership & External Stakeholders to Demonstrate ROI of Medical Affairs Activities

Senior Director - Innovation Lead, Bayer
  • Learn practical strategies to communicate ROI by linking Medical Affairs activities to tangible outcomes such as improved patient access, enhanced clinical-decision making and accelerate product adoption
  • Identify what physicians really need to know and designing interventions that deliver
  • Best practices and lessons learned along the way to overcome common barriers in defining and communicating Medical Affairs value across diverse internal and external stakeholders

11:30 am Roundtable: What Does Medical Affairs Success Look Like? Best Practices & Lessons Learned to Better the Future of this Function

  • Compare how different organisations define the role of Medical Affairs
  • Understand from various perspectives what success looks like, what has and hasn’t worked in demonstrating the value of this function
  • Discuss how the industry can move toward great standardization, while maintaining flexibility across different company models

12:15 pm Lunch Break

Measuring What Matters: Developing KPIs That Go Beyond Numbers to Capture Real Impact

1:15 pm From Insight to Outcome: Building a Measurement Framework that Demonstrates True Medical Affairs Impact

Director, Medical Affairs, Head of Global Insights & Data Analytics, Oncology, Regeneron
  • Move beyond activity-based metrics to focus on high-quality insight generation, identifying meaningful clinical and educational gaps that can shape medical strategy
  • Explore how to leverage AI and multiple data sources to validate field insights, ensuring they are actionable and representative rather than anecdotal
  • Learn how to link insights to tangible outcomes, tracking the impact of Medical Affairs activities on clinical practice, patient pathways, and overall patient outcomes

Roundtable:

Developing KPIs for Different Medical Subfunctions

Medical Communications

1:45 pm Medical Communications

  • Discuss how KPIs differ depending on focus
  • How to track whether educational activities are translating into improved knowledge awareness or clinical adoption
  • Explore ways to show link activities to outcomes
Field Medical & MSLS
Development/ Clinical Trials
Launch Medical Affairs

2:30 pm Afternoon Break & Networking

3:30 pm Using Scientific Alignment Frameworks to Quantify Medical Affairs Impact

Executive Director, Medical Excellence, Amicus Therapeutics
  • Introduce structured “belief mapping” approaches to assess HCP alignment with key scientific statements, moving beyond activity metrics to measure shifts in scientific understanding
  • Identify baseline knowledge gaps and track how engagement strategies influence movement along the alignment spectrum over time
  • Explore the challenges and opportunities in demonstrating progress, using alignment data to inform strategy, prioritize engagement, and evidence true scientific impact

Empowering Field Teams to Capture High-Quality Insights and Demonstrate the Value of Every Scientific Interaction (Capturing the Voice of the Field)

4:00 pm Panel: Conversations from the Field – What do MSLs Want You to Know About Their Work

Associate Director Field Medical Affairs, Regeneron Pharmaceuticals
Senior Medical Science Liaison, Compass Pathways
National Director - Rare Disease Medical Affairs Lead & MSL, Alnylam Pharmaceuticals
  • Hear what drives MSL activities and what factors make engagements most impactful
  • Gain first-hand perspectives from MSLs on the realties of field interactions and the challenges of insight generation
  • What activities and points do field teams want senior leadership and stakeholders to be aware of from their work to show their contribution to decision making

4:45 pm Translating Field Insights into Actionable Evidence to Better Inform Clinical Development & Improve Patient Outcomes

National Director - Rare Disease Medical Affairs Lead & MSL, Alnylam Pharmaceuticals
  • Identify which questions truly reveal scientific gaps, build awareness and support adoption versus less actionable information
  • Which HCPs to engage, how do best identify these individuals
  • Learn which interactions are changing minds discover how collected insights can shape protocols, trial design and patient-centric approaches

5:15 pm Chair’s Closing Remarks

Senior Director - Innovation Lead, Bayer

5:20 pm End of Conference Day One